|
1
|
Sengupta S, Marrinan J, Frishman C and
Sampath P: Impact of temozolomide on immune response during
malignant glioma chemotherapy. Clin Dev Immunol. 2012:8310902012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shinojima N, Tada K, Shiraishi S, Kamiryo
T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, Oka
K, Ishimaru Y and Ushio Y: Prognostic value of epidermal growth
factor receptor in patients with glioblastoma multiforme. Cancer
Res. 63:6962–6970. 2003.PubMed/NCBI
|
|
3
|
Jagannathan J, Prevedello DM, Dumont AS
and Laws ER: Cellular signaling molecules as therapeutic targets in
glioblastoma multiforme. Neurosurg Focus. 20:E82006.PubMed/NCBI
|
|
4
|
De Ridder L: Behaviour of gliomas in vitro
vs histopathological grading. Int J Dev Neurosci. 17:541–546.
1999.PubMed/NCBI
|
|
5
|
Doroshow JH: Anthracycline
antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl
radical production by NADH dehydrogenase. Cancer Res. 43:4543–4551.
1983.
|
|
6
|
Tewey KM, Rowe TC, Yang L, Halligan BD and
Liu LF: Adriamycin-induced DNA damage mediated by mammalian DNA
topoisomerase II. Science. 226:466–468. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mukhopadhyay P, Rajesh M, Bátkai S,
Kashiwaya Y, Haskó G, Liaudet L, Szabó C and Pacher P: Role of
superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced
cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol.
296:H1466–H1483. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rafiyath SM, Rasul M, Lee B, Wei G, Lamba
G and Liu D: Comparison of safety and toxicity of liposomal
doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp
Hematol Oncol. 1:102012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Carneiro T, Khair L, Reis CC, Borges V,
Moser BA, Nakamura TM and Ferreira MG: Telomeres avoid end
detection by severing the checkpoint signal transduction pathway.
Nature. 467:228–232. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
de Lange T: How telomeres solve the
end-protection problem. Science. 326:948–952. 2009.PubMed/NCBI
|
|
11
|
Shay JW and Bacchetti S: A survey of
telomerase activity in human cancer. Eur J Cancer. 33:787–791.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Falchetti ML, Fiorenzo P, Mongiardi MP,
Petrucci G, Montano N, Maira G, Pierconti F, Larocca LM, Levi A and
Pallini R: Telomerase inhibition impairs tumor growth in
glioblastoma xenografts. Neurol Res. 28:532–537. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Harada K, Kurisu K, Tahara H and Tahara E,
Ide T and Tahara E: Telomerase activity in primary and secondary
glioblastomas multiforme as a novel molecular tumor marker. J
Neurosurg. 93:618–625. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lai XF, Shen CX, Wen Z, Qian YH, Yu CS,
Wang JQ, Zhong PN and Wang HL: PinX1 regulation of telomerase
activity and apoptosis in nasopharyngeal carcinoma cells. J Exp
Clin Cancer Res. 31:122012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chang Q, Pang JC, Li J, Hu L, Kong X and
Ng HK: Molecular analysis of PinX1 in medulloblastomas. Int J
Cancer. 109:309–314. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hawkins GA, Chang BL, Zheng SL, Isaacs SD,
Wiley KE, Bleecker ER, Walsh PC, Meyers DA, Xu J and Isaacs WB:
Mutational analysis of PINX1 in hereditary prostate cancer.
Prostate. 60:298–302. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oh BK, Chae KJ, Park C and Park YN:
Molecular analysis of PinX1 in human hepatocellular carcinoma.
Oncol Rep. 12:861–866. 2004.PubMed/NCBI
|
|
18
|
Zhou XZ and Lu KP: The
PIN2/TRF1-interacting protein PINX1 is a potent telomerase
inhibitor. Cell. 107:347–359. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guglielmi B and Werner M: The yeast
homolog of human PinX1 is involved in rRNA and small nucleolar RNA
maturation, not in telomere elongation inhibition. J Biol Chem.
277:35712–35719. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang B, Bai YX, Ma HH, Feng F, Jin R,
Wang ZL, Lin J, Sun SP, Yang P, Wang XX, Huang PT, Huang CF, Peng
Y, Chen YC, Kung HF and Huang JJ: Silencing PinX1 compromises
telomere length maintenance as well as tumorigenicity in
telomerase-positive human cancer cells. Cancer Res. 69:75–83. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jackson AL, Bartz SR, Schelter J,
Kobayashi SV, Burchard J, Mao M, Li B, Cavet G and Linsley PS:
Expression profiling reveals off-target gene regulation by RNAi.
Nat Biotechnol. 21:635–637. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Malek A, Merkel O, Fink L, Czubayko F,
Kissel T and Aigner A: In vivo pharmacokinetics, tissue
distribution and underlying mechanisms of various PEI(−PEG)/siRNA
complexes. Toxicol Appl Pharmacol. 236:97–108. 2009.
|
|
23
|
Moghimi SM, Hunter AC and Murray JC:
Nanomedicine: current status and future prospects. FASEB J.
19:311–330. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Alwi R, Telenkov S, Mandelis A, Leshuk T,
Gu F, Oladepo S and Michaelian K: Silica-coated super paramagnetic
iron oxide nanoparticles (SPION) as biocompatible contrast agent in
biomedical photoacoustics. Biomed Opt Express. 3:2500–2509. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun S, Zeng H, Robinson DB, Raoux S, Rice
PM, Wang SX and Li G: Monodisperse MFe2O4 (M
= Fe, Co, Mn) nanoparticles. J Am Chem Soc. 126:273–279. 2004.
|
|
26
|
Chen G, Chen W, Wu Z, Yuan R, Li H, Gao J
and Shuai X: MRI-visible polymeric vector bearing CD3 single chain
antibody for gene delivery to T cells for immunosuppression.
Biomaterials. 30:1962–1970. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tromsdorf UI, Bigall NC, Kaul MG, Bruns
OT, Nikolic MS, Mollwitz B, Sperling RA, Reimer R, Hohenberg H,
Parak WJ, Förster S, Beisiegel U, Adam G and Weller H: Size and
surface effects on the MRI relaxivity of manganese ferrite
nanoparticle contrast agents. Nano Lett. 7:2422–2427. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ito H, Miller SC, Billingham ME, Akimoto
H, Torti SV, Wade R, Gahlmann R, Lyons G, Kedes L and Torti FM:
Doxorubicin selectively inhibits muscle gene expression in cardiac
muscle cells in vivo and in vitro. Proc Natl Acad Sci USA.
87:4275–4279. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zwiorek K, Kloeckner J, Wagner E and
Coester C: Gelatin nanoparticles as a new and simple gene delivery
system. J Pharm Pharm Sci. 7:22–28. 2005.PubMed/NCBI
|
|
30
|
Medarova Z, Pham W, Farrar C, Petkova V
and Moore A: In vivo imaging of siRNA delivery and silencing in
tumors. Nat Med. 13:372–377. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Murnane JP: Telomere dysfunction and
chromosome instability. Mutat Res. 730:28–36. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ding Z, Wu CJ, Jaskelioff M, Ivanova E,
Kost-Alimova M, Protopopov A, Chu GC, Wang G, Lu X, Labrot ES, Hu
J, Wang W, Xiao Y, Zhang H, Zhang J, Zhang J, Gan B, Perry SR,
Jiang S, Li L, Horner JW, Wang YA, Chin L and DePinho RA:
Telomerase reactivation following telomere dysfunction yields
murine prostate tumors with bone metastases. Cell. 148:896–907.
2012. View Article : Google Scholar : PubMed/NCBI
|
